Table 3.

Summary of retrospectively identified long-term safety and other selected endpoints.

	MVC 300 mg b.i.d. (n = 360) PY = 1243.3				EFV 600 mg q.d. (n = 361) PY = 1204.1
	Total events	n (%)	Raw ratea	Exposure-adjusted rateb	Total events	n (%)	Raw ratea	Exposure-adjusted rateb
Any event	50	38 (10.6)	4.0	3.3	62	45 (12.5)	5.1	4.0
Hepatic failure	0	0	0.0	0.0	0	0 (0.0)	0.0	0.0
MI/cardiac ischemia	6	5 (1.4)	0.5	0.4	6	6 (1.7)	0.5	0.5
Malignancies	8	7 (1.9)	0.6	0.6	14	13 (3.6)	1.2	1.1
CDC category C events	12	11 (3.1)	1.0	0.9	16	14 (3.9)	1.3	1.2
Infections reported as serious AEs	28	24 (6.7)	2.3	2.0	35	25 (6.9)	2.9	2.2
Rhabdomyolysis	0	0	0.0	0.0	0	0	0.0	0.0

AE, adverse event; b.i.d., twice daily; CDC, Center for Disease Control; EFV, efavirenz; MI, myocardial infarction; MVC, maraviroc; PY, patient-years; q.d., once daily.

^aTotal number of events/100 PY.

^bEvents/100 PY based on time to first event.